WaferGen and Qiagen to Promote Genomics Platform Products in Japan

Life Science Investing News

WaferGen Bio-systems Inc. (OTC Pink:WGBS) announced that it plans to jointly promote certain products in the area of genomics platforms with Qiagen KK, a subsidiary of Qiagen NV (NASDAQ:QGEN). The promotion will take place in Japan and will involve Next-Gen sequencing and qPCR.

WaferGen Bio-systems Inc. (OTC Pink:WGBS) announced that it plans to jointly promote certain products in the area of genomics platforms with Qiagen KK, a subsidiary of Qiagen NV (NASDAQ:QGEN). The promotion will take place in Japan and will involve Next-Gen sequencing and qPCR.

As quoted in the press release:

With the joint offering, customers will be able to seamlessly plan and execute complex research projects involving molecular biomarker discovery with NGS, where WaferGen’s SmartChip will offer a powerful platform for high-throughput qPCR-based target validation. The purpose of the commercial relationship is to help life science researchers accelerate the process of developing markers that are potential candidates for molecular diagnostics by adding WaferGen’s SmartChip solution to facilitate biomarker validation.

Click here to read the full WaferGen Bio-systems Inc. (OTC Pink:WGBS) press release.

The Conversation (0)
×